Atlas Trials

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

Clinical trial NCT01843062 · TERMINATED

Trial details

NCT number
NCT01843062
Sponsor
AstraZeneca
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Differentiated Thyroid Cancer
Start date
2013-08-27
Primary completion
2018-05-18
Enrollment
233

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.